Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CADLNASDAQ:LIMNNASDAQ:PVLANASDAQ:QNTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCADLCandel Therapeutics$5.10+2.2%$5.23$3.79▼$14.60$255.51M-0.911.48 million shs619,068 shsLIMNLiminatus Pharma$9.02+2.4%$0.00$4.40▼$33.66$234.61MN/A438,335 shs196,150 shsPVLAPalvella Therapeutics$24.12+1.2%$23.29$6.20▼$29.27$266.77M-0.11130,255 shs40,233 shsQNTMQuantum Biopharma$17.15-10.5%$15.11$2.70▼$38.25$49.91M0.67920,920 shs330,019 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCADLCandel Therapeutics0.00%+4.08%-15.56%+5.37%-12.37%LIMNLiminatus Pharma0.00%-4.85%+901,999,900.00%+901,999,900.00%+901,999,900.00%PVLAPalvella Therapeutics0.00%+9.24%-5.04%+20.18%+2,411,999,900.00%QNTMQuantum Biopharma0.00%-21.04%+11.00%+169.65%+1,714,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCADLCandel Therapeutics2.4791 of 5 stars3.51.00.00.03.31.70.6LIMNLiminatus PharmaN/AN/AN/AN/AN/AN/AN/AN/APVLAPalvella Therapeutics3.3999 of 5 stars3.60.00.00.02.84.20.6QNTMQuantum BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCADLCandel Therapeutics 3.00Buy$22.00331.37% UpsideLIMNLiminatus Pharma 0.00N/AN/AN/APVLAPalvella Therapeutics 3.13Buy$46.2991.90% UpsideQNTMQuantum Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest QNTM, LIMN, CADL, and PVLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$23.006/18/2025QNTMQuantum BiopharmaSingular ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy5/16/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$53.00 ➝ $52.004/30/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/11/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/9/2025PVLAPalvella TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$50.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCADLCandel Therapeutics$120K2,129.25N/AN/A$1.41 per share3.62LIMNLiminatus PharmaN/AN/AN/AN/AN/AN/APVLAPalvella Therapeutics$42.81M6.23N/AN/A$5.58 per share4.32QNTMQuantum BiopharmaN/AN/AN/AN/A$4.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCADLCandel Therapeutics-$55.18M-$1.34N/AN/AN/AN/A-136.74%-63.13%8/12/2025 (Estimated)LIMNLiminatus PharmaN/AN/A0.00∞N/AN/AN/AN/AN/APVLAPalvella Therapeutics-$17.43M-$12.10N/AN/AN/AN/A-60.29%-43.30%8/13/2025 (Estimated)QNTMQuantum Biopharma-$14.20M-$15.98N/AN/AN/AN/A-155.20%-94.90%8/13/2025 (Estimated)Latest QNTM, LIMN, CADL, and PVLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PVLAPalvella Therapeutics-$3.40-$0.74+$2.66-$0.74N/AN/A5/14/2025Q1 2025QNTMQuantum Biopharma-$0.37-$1.41-$1.04-$3.53$2.09 million$2.09 million5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCADLCandel TherapeuticsN/AN/AN/AN/AN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCADLCandel Therapeutics0.014.644.64LIMNLiminatus PharmaN/AN/AN/APVLAPalvella TherapeuticsN/A8.848.84QNTMQuantum BiopharmaN/A0.960.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCADLCandel Therapeutics13.93%LIMNLiminatus PharmaN/APVLAPalvella Therapeutics40.11%QNTMQuantum Biopharma1.24%Insider OwnershipCompanyInsider OwnershipCADLCandel Therapeutics16.60%LIMNLiminatus PharmaN/APVLAPalvella Therapeutics20.50%QNTMQuantum Biopharma8.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCADLCandel Therapeutics6050.10 million41.79 millionOptionableLIMNLiminatus PharmaN/A26.01 millionN/AN/APVLAPalvella TherapeuticsN/A11.06 million8.79 millionN/AQNTMQuantum BiopharmaN/A2.91 million2.66 millionN/AQNTM, LIMN, CADL, and PVLA HeadlinesRecent News About These CompaniesQNTM - Quantum BioPharma Ltd Ordinary Shares - MorningstarJuly 3, 2025 | morningstar.comMQuantum BioPharma Announces Private Placement - The Manila TimesJune 29, 2025 | manilatimes.netMQuantum BioPharma completes $600 private placement of voting sharesJune 29, 2025 | investing.comQuantum BioPharma Announces Private Placement of 12 Class A Multiple Voting Shares at a Price of $50 Per Share - Yahoo FinanceJune 29, 2025 | finance.yahoo.comQuantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering - MorningstarJune 27, 2025 | morningstar.comMQuantum BioPharma Announces Private PlacementJune 27, 2025 | globenewswire.comBest Cannabis Stocks To Watch Today - June 26thJune 26, 2025 | marketbeat.comQuantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public OfferingJune 26, 2025 | globenewswire.comCannabis Stocks To Research - June 25thJune 25, 2025 | marketbeat.comTop Cannabis Stocks To Keep An Eye On - June 23rdJune 23, 2025 | marketbeat.comWhat is Singular Research's Estimate for QNTM Q1 Earnings?June 23, 2025 | marketbeat.comQuantum Biopharma (NASDAQ:QNTM) Upgraded at Singular ResearchJune 21, 2025 | marketbeat.comCannabis Stocks To Follow Today - June 20thJune 20, 2025 | marketbeat.comUnbuzzd Wellness Inc Ordinary Shares - Class B (Sub Voting)June 19, 2025 | morningstar.comMQuantum, CyberCatch, Kodiak at 52-Week Highs on NewsJune 18, 2025 | ca.finance.yahoo.comSingular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline ProgressJune 18, 2025 | newsfilecorp.comNKeg, LQWD, Quantum at 52-Week Highs on NewsJune 17, 2025 | baystreet.caCannabis Stocks To Add to Your Watchlist - June 17thJune 17, 2025 | marketbeat.comQuantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General HospitalJune 17, 2025 | globenewswire.comQuantum BioPharma plans special dividend tied to legal actionJune 14, 2025 | investing.comBest Cannabis Stocks To Add to Your Watchlist - June 13thJune 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQNTM, LIMN, CADL, and PVLA Company DescriptionsCandel Therapeutics NASDAQ:CADL$5.10 +0.11 (+2.20%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$5.10 0.00 (0.00%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Liminatus Pharma NASDAQ:LIMN$9.02 +0.21 (+2.38%) As of 07/3/2025 01:00 PM EasternLiminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.Palvella Therapeutics NASDAQ:PVLA$24.12 +0.29 (+1.22%) As of 07/3/2025 01:00 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.Quantum Biopharma NASDAQ:QNTM$17.15 -2.01 (-10.49%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$16.98 -0.17 (-1.02%) As of 04:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
